menu
    • menu

    Company profile for Adaptive Phage Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    In 2003, as multi-drug resistant (MDR) bacteria was starting to pose a serious international health risk, National Institutes of Health (NIH) scientist Carl R. Merril, MD, published a pivotal article that outlined prior limitations of phage therapy and suggested concepts that have emerged as the modern approach. In 2010, the Biological Defense Research Directorate (BDRD) of the US Navy began an initiative to explore Dr. Merril...
    In 2003, as multi-drug resistant (MDR) bacteria was starting to pose a serious international health risk, National Institutes of Health (NIH) scientist Carl R. Merril, MD, published a pivotal article that outlined prior limitations of phage therapy and suggested concepts that have emerged as the modern approach. In 2010, the Biological Defense Research Directorate (BDRD) of the US Navy began an initiative to explore Dr. Merril’s concepts as a potential way to deal with biodefense threats associated with MDR superbugs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Adaptive Phage TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    22 Firstfield Rd, Suite 125 Gaithersburg, MD 20878
    Telephone
    Telephone
    +1-844-972-0500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.aphage.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BiomX Reports Q1 2024 Results, Program Updates
    BiomX Reports Q1 2024 Results, Program Updates

    21 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/21/2885399/0/en/BiomX-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-and-Program-Updates.html

    GLOBENEWSWIRE
    21 May 2024
    Share Share
    BiomX Reports Fourth Quarter and Full Year 2023 Financial Results
    BiomX Reports Fourth Quarter and Full Year 2023 Financial Results

    03 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/03/2856746/0/en/BiomX-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    03 Apr 2024
    Share Share
    BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics
    BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics

    18 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/18/2847627/0/en/BiomX-Announces-Closing-of-the-Acquisition-of-Adaptive-Phage-Therapeutics-and-Concurrent-50-Million-Financing.html

    GLOBENEWSWIRE
    18 Mar 2024
    Share Share
    BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics
    BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics

    06 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/06/2841300/0/en/BiomX-Announces-Entry-into-Merger-Agreement-with-Adaptive-Phage-Therapeutics-and-Concurrent-50-Million-Financing.html

    GLOBENEWSWIRE
    06 Mar 2024
    Share Share
    Adaptive Phage Closes on $12 Million Investment in $30 Million Series B1
    Adaptive Phage Closes on $12 Million Investment in $30 Million Series B1

    13 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230613482846/en

    BUSINESSWIRE
    13 Jun 2023
    Share Share
    Adaptive Phage Therapeutics Enters Collaboration and License Agreement
    Adaptive Phage Therapeutics Enters Collaboration and License Agreement

    24 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230524005291/en

    BUSINESSWIRE
    24 May 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search